Advisory - Bayer expands recall of RestoraLAX, sold nationwide, due to potential choking hazard
OTTAWA, July 8, 2017 /CNW/ -
Issue Further to a recent recall of RestoraLAX 45+10, Health Canada is advising Canadians that Bayer Inc. is expanding its voluntary recall to include specific lots of RestoraLAX 30+7 Bonus Packs sold at various retailers across Canada due to a potential choking hazard.
Specific lots of RestoraLAX 30+7 Bonus Packs may contain deposits such as clumps or lumps.? The presence of these deposits may pose a choking hazard.
RestoraLAX is used to relieve occasional constipation and irregularity.
Who is affected
Consumers who have bought or used the affected RestoraLAX 30+7 Bonus Packs ?sold nationwide.
Affected products The following lots of RestoraLAX 30+7 Bonus Packs (DIN 02318164):
5M03PU
5M09PU
6G02PU
6G03PU
6E25PU
This product is sold as a combination pack: 1 bottle of 30 doses of RestoraLAX powder, shrink wrapped together with 1 bottle of 7 doses of RestoraLAX powder.
What consumers should do
Stop using this product. Seek immediate medical attention if you experience difficulty swallowing or breathing after taking this product.
Consult with your health care professional if you have used it and have health concerns.
Contact Bayer at 1-800-265-7382 or visit bayer.ca if you have questions about this recall.
Report adverse events to health products to Health Canada by calling toll-free at 1?866?234?2345, or by reporting online, by mail or by fax.
Report complaints about health products to Health Canada by calling toll-free at 1?800?267?9675, or complete an online complaint form.
What Health Canada is doing Health Canada is monitoring the company's recall. If new safety information is identified, Health Canada will take appropriate action and inform Canadians as necessary.
Background Bayer Inc. has advised that the issue is associated with a packaging process specific to the RestoraLAX® 45+10 Value Packs and the RestoraLAX 30+7 Bonus Packs, and that no other RestoraLAX packaging formats are impacted or being recalled at this time.
The global gastroesophageal reflux disease (GERD) market size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Rising geriatric...
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...